Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. more
Time Frame | ATXI | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.52% | 1.76% | -2.5% |
1-Month Return | 5.56% | 0.33% | -3.91% |
3-Month Return | -6.17% | -8.58% | -0.59% |
6-Month Return | -45.56% | -4.26% | 3.45% |
1-Year Return | -83.63% | 1.27% | 22.31% |
3-Year Return | -99.81% | 5.33% | 25% |
5-Year Return | -99.98% | 38.09% | 77.23% |
10-Year Return | -99.98% | 102.29% | 188.04% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 26.27M | 5.21M | 3.74M | 8.04M | 14.54M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":19.85,"profit":true},{"date":"2021-12-31","value":14.23,"profit":true},{"date":"2022-12-31","value":30.62,"profit":true},{"date":"2023-12-31","value":55.36,"profit":true}] |
Operating Income | (26.27M) | (5.21M) | (3.74M) | (8.04M) | (14.54M) | [{"date":"2019-12-31","value":-2626500000,"profit":false},{"date":"2020-12-31","value":-521300000,"profit":false},{"date":"2021-12-31","value":-373800000,"profit":false},{"date":"2022-12-31","value":-804300000,"profit":false},{"date":"2023-12-31","value":-1454000000,"profit":false}] |
Total Non-Operating Income/Expense | 714.00K | 124.00K | 14.00K | 3.30M | 3.85M | [{"date":"2019-12-31","value":18.56,"profit":true},{"date":"2020-12-31","value":3.22,"profit":true},{"date":"2021-12-31","value":0.36,"profit":true},{"date":"2022-12-31","value":85.8,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (25.91M) | (5.15M) | (3.73M) | (3.60M) | (10.49M) | [{"date":"2019-12-31","value":-2590800000,"profit":false},{"date":"2020-12-31","value":-515100000,"profit":false},{"date":"2021-12-31","value":-373100000,"profit":false},{"date":"2022-12-31","value":-360300000,"profit":false},{"date":"2023-12-31","value":-1048800000,"profit":false}] |
Income Taxes | (357.00K) | (62.00K) | (7.00K) | (5.65M) | (111.00K) | [{"date":"2019-12-31","value":-35700000,"profit":false},{"date":"2020-12-31","value":-6200000,"profit":false},{"date":"2021-12-31","value":-700000,"profit":false},{"date":"2022-12-31","value":-565100000,"profit":false},{"date":"2023-12-31","value":-11100000,"profit":false}] |
Income After Taxes | (25.55M) | (5.09M) | (3.72M) | 2.05M | (10.38M) | [{"date":"2019-12-31","value":-1247.61,"profit":false},{"date":"2020-12-31","value":-248.49,"profit":false},{"date":"2021-12-31","value":-181.84,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-506.69,"profit":false}] |
Income From Continuous Operations | (25.91M) | (5.15M) | (3.73M) | (3.60M) | (10.49M) | [{"date":"2019-12-31","value":-2590800000,"profit":false},{"date":"2020-12-31","value":-515100000,"profit":false},{"date":"2021-12-31","value":-373100000,"profit":false},{"date":"2022-12-31","value":-360300000,"profit":false},{"date":"2023-12-31","value":-1048800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (25.55M) | (5.09M) | (3.72M) | 2.05M | (10.38M) | [{"date":"2019-12-31","value":-1247.61,"profit":false},{"date":"2020-12-31","value":-248.49,"profit":false},{"date":"2021-12-31","value":-181.84,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-506.69,"profit":false}] |
EPS (Diluted) | (25.80) | (4.65) | (2.60) | (1.28) | (1.75) | [{"date":"2019-12-31","value":-2580,"profit":false},{"date":"2020-12-31","value":-465,"profit":false},{"date":"2021-12-31","value":-260,"profit":false},{"date":"2022-12-31","value":-128.17,"profit":false},{"date":"2023-12-31","value":-175,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ATXI | |
---|---|
Cash Ratio | 2.67 |
Current Ratio | 2.70 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ATXI | |
---|---|
ROA (LTM) | -201.35% |
ROE (LTM) | -535.10% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ATXI | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.37 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.99 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ATXI | |
---|---|
Trailing PE | 0.07 |
Forward PE | 17.99 |
P/S (TTM) | 0.00 |
P/B | 1.43 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
PEG | NM |
Avenue Therapeutics Inc (ATXI) share price today is $1.9
Yes, Indians can buy shares of Avenue Therapeutics Inc (ATXI) on Vested. To buy Avenue Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ATXI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Avenue Therapeutics Inc (ATXI) via the Vested app. You can start investing in Avenue Therapeutics Inc (ATXI) with a minimum investment of $1.
You can invest in shares of Avenue Therapeutics Inc (ATXI) via Vested in three simple steps:
The 52-week high price of Avenue Therapeutics Inc (ATXI) is $15. The 52-week low price of Avenue Therapeutics Inc (ATXI) is $1.6.
The price-to-earnings (P/E) ratio of Avenue Therapeutics Inc (ATXI) is 0.0731
The price-to-book (P/B) ratio of Avenue Therapeutics Inc (ATXI) is 1.43
The dividend yield of Avenue Therapeutics Inc (ATXI) is 0.00%
The market capitalization of Avenue Therapeutics Inc (ATXI) is $3.90M
The stock symbol (or ticker) of Avenue Therapeutics Inc is ATXI